Dataset opportunity
Medistri — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Medistri, usable for Diagnostic AI and Computer Vision.
Score
65.7
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Acquire
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global Artificial Intelligence in Diagnostics market = $2.0 billion in 2025, CAGR 21.7%.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- ✨Signal
Medistri Laboratory technical infrastructure and validation services
source ↗
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Mixed ownership — licensing rights to clarify · PII/regulated
Buyer persona
Medical-AI & diagnostic-imaging companies
Medistri holds a specialized Medical Imaging Dataset in the Image modality, derived from its core healthcare services. The data is substantiated by industrial records, `medical_records`, and regulatory filings, providing a highly structured and traceable collection ideal for training and validating Diagnostic AI models for tasks such as anomaly detection and quality control in medical device testing.
This dataset is positioned within the rapidly growing AI in Diagnostics market, which was valued at $2.0 billion in 2025 and is projected to expand at a CAGR of 21.7%. [2, 4] While access is subject to negotiation due to strict regulatory standards like ISO 13485 and client confidentiality agreements, the rarity and high-fidelity nature of this compliance-grade data represent a significant competitive advantage for AI developers, justifying the diligence required to access it. ⚠ Diligence (valuable data, access to negotiate): Data subject to strict medical and pharmaceutical regulatory standards (ISO 13485, FDA); Confidentiality agreements with MedTech/Pharma clients regarding specific test results; Technical data likely siloed within industrial control systems and LIMS (Laboratory Information Management Systems) · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Medistri owns a proprietary dataset of imagery and logs from the sterility testing and chemical analysis of medical devices. This data is critical for AI buyers developing automated diagnostic AI for laboratory and quality control settings, a key segment of the rapidly growing AI in Diagnostics market. With this market projected to reach $2.0 billion by 2025, this rare dataset provides the ground truth needed to train models for high-stakes industrial applications, offering a significant competitive advantage.
See dimension details ↓- Data Orientation39
1 data-appetite signals (1 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — Medistri is a good target as its core business is contract sterilization and laboratory services for the medical industry, which generates valuable operational data as a by-product without any indication of it being sold. Issues: The initial prompt mentioned a 'Medical Imaging Dataset Opportunity', but the company's actual business is contract sterilization and lab services. The data gen
- Deep Qualification90
⚠ needs review — Medistri is a contract service organization for the MedTech industry holding valuable device performance and validation data. However, this data is owned by its clients and subject to confidentiality, making third-party monetization highly unlikely. [data is owned by the company's customers; licensing restricted; dataset_type implausible vs real activity: The label 'Medical Imaging Dataset' is misleading. Medistri's services involve sterilisation and laboratory testing of medical devices, not clinical imaging. Any generated images would be for industrial quality control of devices or packaging (e.g., dye penetration tests, microscopy), not diagnostic medical images (X-ray, MRI). [2, 6]]
- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
Buyer demand is exceptionally high, driven by a competitive race to capture a share of the AI in Diagnostics market, which is projected to grow at a 21.7% CAGR. [2, 4]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License36
ownership=mixed, licensing=rights_unclear
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Industrial data
The company holds detailed time-series data from industrial sterilization processes, which is valuable for developing predictive maintenance and process optimization AI for medical manufacturing.
Medical records / imaging
This is a proprietary collection of images from bioburden testing and chemical analysis, essential for training computer vision models to automate quality control and safety checks for medical devices.
Regulatory records
The dataset includes proprietary textual records on sterilization validation and environmental monitoring, providing crucial context for building AI systems that meet stringent regulatory and compliance standards.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Medistri Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global Artificial Intelligence in Diagnostics market = $2.0 billion in 2025, CAGR 21.7% (source: Grand View Research). Investment score 65.7/100 (confidence 0.49). Recommended action: Acquire.
From the marketplace
Explore live data opportunities
Uoc Europe — Medical Imaging Dataset Opportunity
View opportunity →healthcareStarseq — Medical Imaging Dataset Opportunity
View opportunity →healthcareIcentia — Medical Imaging Dataset Opportunity
View opportunity →